Hypertrophic scar

Enlyte Announces Winners of 2023 Heart of Case Management Awards

Retrieved on: 
Wednesday, October 11, 2023
Shortage, Pain, Male, IVC, Falling, Family, Burn, Paralysis, Knee, Thrombosis, Pulmonary artery, Chest pain, PBM, Embolism, Risk, Cardiology, Communication, Injury, T-11, Concussion, Neurology, Electricity, Arm, Trust, Motivation, Education, Hypertrophic scar, CT, SVP, Artery, SAN, Head, ICU, Case management, Shoulder, Burns, Hematology, Tracheotomy, Medical case management, Quality of life, Nursing, Health insurance, Genex Power

SAN DIEGO, Oct. 11, 2023 /PRNewswire/ -- Enlyte, a leader in cost-containment technology, provider networks, clinical services, pharmacy benefit management (PBM) and disability management, has announced the winners of the 2023 Heart of Case Management Awards, a prestigious honor recognizing four individuals nominated by their managers and selected from a field of more than 2,000 case managers across the country.

Key Points: 
  • SAN DIEGO, Oct. 11, 2023 /PRNewswire/ -- Enlyte, a leader in cost-containment technology, provider networks, clinical services, pharmacy benefit management (PBM) and disability management, has announced the winners of the 2023 Heart of Case Management Awards, a prestigious honor recognizing four individuals nominated by their managers and selected from a field of more than 2,000 case managers across the country.
  • This was the case for this year's winners of Genex's Heart of Case Management Awards, who overcame overwhelming odds to help injured employees meet their recovery goals.
  • Among this year's winners is a case manager who used her critical thinking skills to allow an Amish builder to return to function following a spinal cord injury.
  • Nominees are judged on a multitude of criteria including expertise, excellence, adaptability, trust, influential communication, critical thinking and outcomes.

Galderma and National Breast Cancer Foundation Announce Continued Partnership to Launch Campaign Elevating Skin Stories of Breast Cancer Survivors

Retrieved on: 
Monday, October 3, 2022
Lip, History, Toxin (comics), Anaphylaxis, Lists of diseases, Safety, Pimple, Warfarin, Skin discoloration, Allergy, Swelling, Vitamin, Coagulopathy, Cheek, Victory Unintentional, Myasthenia gravis, Skin, Bleeding, Face, Rash, Upper respiratory tract infection, Recurrence, Headache, Skin infection, Lidocaine, Human, Patient, Severe cognitive impairment, Infection, Blood, Nausea, Bruise, ALS, Inflammation, Muscle, Amyotrophic lateral sclerosis, Red, Medication, Restylane, Aspirin, Muscle weakness, Nose, Tenderness, Wound, Multimedia, Pain, FDA, Herbal, Cyst, Vascular occlusion, Risk, Scar, Bacteria, Hypertrophic scar, Stroke, Sculptra, Catherine Disher, Infarction, Death, Hyaluronic acid, Eyebrow, Laser, Galderma, Use, Cosmetics, Canning, Birth control, Dietary supplement, Pharmaceutical industry, Medicine, Tissue paper, Botulinum toxin

These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.

Key Points: 
  • These effects could make it unsafe for you to drive a car, operate machinery, or do other dangerous activities.
  • Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal and other natural products.
  • Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete.
  • Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area.

Innovation1 Biotech Appoints Frederick E. Pierce, II to its Board of Directors

Retrieved on: 
Thursday, September 15, 2022
Burn, Income, II, Glycogenesis, Inflammation, Senior advisor, Kidder, Peabody & Co., Hampshire College, Sale, Lehman Brothers, U.S. Securities and Exchange Commission, Schedule 1, Company, Fibromyalgia, OTCQB, Depression, Intellectual property, Private Securities Litigation Reform Act, Review, Climate Leadership Council, Hypertrophic scar, Cornea, Consulate, Epilepsy, Chronic fatigue syndrome, CEO, Genetics, List of life sciences, Acceleration, Investor relations, Solution, Cannabis, Board of directors, The Company, Merrill (company), Board, Security (finance), Post-traumatic stress disorder, SemBioSys Genetics, Fatigue, Marketing, GLOBE, Business development, Pharmaceutical industry, Management, Chemistry

Mr. Pierce is a serial biotech entrepreneur with more than 20 years of senior leadership and operating experience in building successful biotech companies.

Key Points: 
  • Mr. Pierce is a serial biotech entrepreneur with more than 20 years of senior leadership and operating experience in building successful biotech companies.
  • He is the CEO and co-founder of Decoy Therapeutics, a pharmaceutical company that has created a rapid antivirals development platform.
  • As a board member of the Canadian Entrepreneurs of New England, he serves as Chairman of the Life Sciences Leadership Council.
  • Mr. Pierce brings a wealth of experience to our Board of Directors.

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Retrieved on: 
Monday, August 29, 2022
RNA interference, Liver cancer, Laser, AES, Metastasis, Scar, RNA, Safety, CEO, Squamous cell carcinoma, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Basal-cell carcinoma, Liver, Food and Drug Administration, Doctor of Philosophy, CR, PSC, Head, Population, Board, Skin, Phase, Infection, Radiation, Food, Injection, Neck, Behzad Razavi, Incidence, Cryosurgery, SCC, NMPA, Lymph, BCC, MD, Sirna, Company, FDA, Therapy, Șaeș, PNP, Cancer, Cholangiocarcinoma, NMSC, Bleeding, Risk, HTS, Face, Clinical trial, Primary sclerosing cholangitis, CCA, Hypertrophic scar, Patient, Pharmaceutical industry

GAITHERSBURG, Md and SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the cohort receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response (CR), indicating the promising viability of the treatment. STP705 is a siRNA (small interfering RNA) therapeutic that is composed of two siRNA oligonucleotides, targeting the expression of TGF-β1 and COX-2 mRNA, respectively.

Key Points: 
  • The Company is continuing to explore doses in the ongoing dose escalation study and anticipates a final report in Q1 2023.
  • "Based on the successes of both BCC and isSCC (cutaneous squamous cell carcinoma in situ) clinical studies, Sirnaomics is spearheading the development of the novel polypeptide-based siRNA therapeutics for various types of cancers."
  • Basal cell carcinoma (BCC) is a type of nonmelanoma skin cancer (NMSC) that is associated with exposure to ultraviolet radiation from the sun.
  • STP705 is currently in seven clinical trials for different indications: a Phase IIb for squamous cell carcinoma in situ (isSCC), a Phase II for basal cell carcinoma (BCC), a Phase I/II for keloid scarring, a Phase I/II for hypertrophic scar (HTS), a Phase I/II for facial isSCC, a Phase I for liver cancer (basket), and a Phase I for medical cosmetology treatment.

Innovation1 Biotech Announces Filing of Patent Application for Novel Combination Therapy Targeting Addiction

Retrieved on: 
Thursday, August 18, 2022
Intellectual property, U.S. Securities and Exchange Commission, Depression, Inflammation, CEO, GLOBE, Lists of diseases, Private Securities Litigation Reform Act, Patent, Brain, Sale, Security (finance), Substance abuse, United States Patent and Trademark Office, The Company, Burn, Income, Marketing, Review, Fatigue, Company, Addiction, Therapy, Cannabis, Hypertrophic scar, THCV, Epilepsy, Nicotine, Cocaine, Post-traumatic stress disorder, OTCQB, Fibromyalgia, Chronic fatigue syndrome, Ibogaine, Cornea, USPTO, Schedule 1, Pharmaceutical industry

In contrast to traditional approaches to treat addiction, Innovation1s combination therapy is designed to rewire neural networks to combat drug addiction by suppressing cravings and blocking withdrawal symptoms of opiates, alcohol, and nicotine.

Key Points: 
  • In contrast to traditional approaches to treat addiction, Innovation1s combination therapy is designed to rewire neural networks to combat drug addiction by suppressing cravings and blocking withdrawal symptoms of opiates, alcohol, and nicotine.
  • The patent application uniquely combines therapeutics that target different aspects of the alpha3beta4 nicotinic acetylcholine receptor.
  • A second component, a synthetic analog of ibogaine designated 18-MAC, directly antagonizes the ligand binding to this receptor.
  • This patent represents another key step at a differentiated approach to help all who suffer from addiction, said Jeffrey Kraws, CEO of Innovation1 Biotech.

OliX Pharmaceuticals Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-related Macular Degeneration

Retrieved on: 
Wednesday, August 3, 2022
Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Inflammation, AMD, Geographic atrophy, RNA interference, RNA, Hypertrophic scar, Food, Patient, Company, Safety, GA, FDA, IND, Technology, Disorder, Institute of Liver and Biliary Sciences, Vance DeGeneres, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, KOSDAQ, Pharmaceutical industry

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved the Companys Investigational New Drug (IND) application to develop OLX10212 for the treatment of age-related macular degeneration (AMD).

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved the Companys Investigational New Drug (IND) application to develop OLX10212 for the treatment of age-related macular degeneration (AMD).
  • Dong Ki Lee, Ph.D., Founder and Chief Executive Officer of OliX Pharmaceuticals, commented, FDA approval of the IND for OLX10212 marks a significant milestone in expanding OliXs commitment to the treatment of ophthalmic diseases.
  • With the FDA approval of the IND application for OLX10212, the Company has entered clinical trials for two investigational therapeutic programs in the U.S.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Global Hypertrophic & Keloid Scar Treatment Market Research Report to 2027 - Players Include CCA Industries, Cynosure, Honeydew Products and HRA Pharma - ResearchAndMarkets.com

Retrieved on: 
Friday, July 1, 2022
Other Consumer, Surgery, Medical Supplies, Women, Men, General Health, Pharmaceutical, Consumer, Health, Cosmetics, Acquisition, Decision-making, USD, Strategic management, Market share analysis, Value, R, Business Growth Fund, COVID-19, Customer support, Growth, Hypertrophic scar, Investment, Certification, CAGR, Hypertrophy, Use, Retail, Medical device, Beauty salon

The "Hypertrophic & Keloid Scar Treatment Market Research Report by Scar Type (Hypertrophic Scar and Keloid Scar), Product, End-use, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hypertrophic & Keloid Scar Treatment Market Research Report by Scar Type (Hypertrophic Scar and Keloid Scar), Product, End-use, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hypertrophic & Keloid Scar Treatment Market?
  • What is the market share of the leading vendors in the Global Hypertrophic & Keloid Scar Treatment Market?
  • What modes and strategic moves are considered suitable for entering the Global Hypertrophic & Keloid Scar Treatment Market?

OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease

Retrieved on: 
Wednesday, June 15, 2022
Health, Genetics, Research, Science, Pharmaceutical, Optical, Biotechnology, RNA, Patent, Therapy, Institute of Liver and Biliary Sciences, Neuropathic pain, Technology, Hypertrophic scar, AMD, CRISPR, Plant, Research, Cas9, Eukaryote, RNA interference, Eye, Disorder, RNA transfection, Pharmaceutical industry, Vaccine

OliX Pharmaceuticals, Inc. , a leading developer of RNAi therapeutics, today announced that the Companys subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureXs mRNA technology.

Key Points: 
  • OliX Pharmaceuticals, Inc. , a leading developer of RNAi therapeutics, today announced that the Companys subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureXs mRNA technology.
  • The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
  • Once we clinically validate the technology, we plan to expand the indications of treatments to various non-hereditary eye diseases as well.
  • OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.

OliX Pharmaceuticals to Conduct Business Meetings with Potential Partners at 2022 BIO International Convention

Retrieved on: 
Thursday, June 9, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Genetics, Other Health, Company, NASH, RNA interference, RNA, Hair loss, Neuropathic pain, KOSDAQ, AMD, Hepatitis B virus, June Park, Florida, Therapy, HBV, Technology, Fatty liver disease, Institute of Liver and Biliary Sciences, Hypertrophic scar, Vaccine

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Companys management will participate in one-on-one partnering meetings at the 2022 BIO International Convention , being held in-person from June 13 to 16, 2022.

Key Points: 
  • OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Companys management will participate in one-on-one partnering meetings at the 2022 BIO International Convention , being held in-person from June 13 to 16, 2022.
  • Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, and June Park, Ph.D., Head of R&D at OliX Pharmaceuticals, will meet global industry experts to discuss platform-based early discovery collaborations as well as global licensing options for the Companys pipeline programs.
  • OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology.
  • OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium

Retrieved on: 
Wednesday, June 8, 2022
Science, Other Science, Biotechnology, Research, Surgery, Health, FDA, Clinical Trials, Blood, Wound, Inflammation, Pain, PLLA, Allergy, Toxin (comics), Vascular occlusion, Skin infection, Herbal, Muscle, History, Galderma, Hypertrophic scar, Tenderness, Human, Infection, Headache, Vitamin, Partnership, Bleeding, Myasthenia gravis, Red, Rash, Bajaj Consumer Care, Dermatology, Pimple, Sculptra, Catherine Disher, Infarction, Nausea, Bruise, Lip, Patient, ALS, Muscle weakness, Skin, Cyst, Skin discoloration, Use, Research, Nose, Medication, Amyotrophic lateral sclerosis, Upper respiratory tract infection, FDA, Risk, Face, Safety, Eyebrow, Death, Pharmaceutical industry, Cosmetics, Canning, Birth control, Dietary supplement, Medicine, Aesthetics, EU, Botulinum toxin, Ipsen

Galderma is the worlds largest independent dermatology company, present in approximately 100 countries.

Key Points: 
  • Galderma is the worlds largest independent dermatology company, present in approximately 100 countries.
  • We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine.
  • Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes.
  • Because we understand that the skin were in shapes our life stories, we are advancing dermatology for every skin story.